Novartis AG ADR (NVS)vsOncology Institute Inc (TOI)
NVS
Novartis AG ADR
$146.57
-0.87%
HEALTHCARE · Cap: $282.11B
TOI
Oncology Institute Inc
$4.05
+4.92%
HEALTHCARE · Cap: $366.69M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 11154% more annual revenue ($56.58B vs $502.73M). NVS leads profitability with a 23.9% profit margin vs -12.1%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$146.57
$36.97 premium
Margin of Safety
+80.1%
Fair Value
$13.17
Current Price
$4.05
$9.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 41.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -652.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a declining stock while TOI is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
TOI is growing revenue faster at 41.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 45/100), backed by strong 23.9% margins. TOI offers better value entry with a 80.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a pioneering healthcare organization dedicated to transforming cancer care through its extensive network of specialized clinics and innovative treatment modalities. The company prioritizes enhanced patient outcomes by leveraging state-of-the-art technologies and customized treatment plans, while also participating in clinical trials and collaborations with leading research institutions. As the need for advanced cancer therapies continues to grow, TOI is strategically positioned to leverage its robust pipeline and deep-seated oncology expertise, reinforcing its status as a key player in the evolving healthcare sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?